Evolution: IMiDs to PPMs, revolution in DLBCL?

Blood. 2015 Aug 6;126(6):698-700. doi: 10.1182/blood-2015-06-649483.

Abstract

In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of diffuse large B-cell lymphoma (DLBCL).

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • B-Lymphocytes / drug effects*
  • Humans
  • Ikaros Transcription Factor / genetics*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Peptide Hydrolases / genetics*
  • Piperidones / pharmacology*
  • Quinazolinones / pharmacology*
  • Signal Transduction / drug effects*

Substances

  • Antineoplastic Agents
  • Piperidones
  • Quinazolinones
  • Ikaros Transcription Factor
  • Peptide Hydrolases